SCHEMBL16629487

SCHEMBL16629487

Cc1cn([C@@H]2O[C@H](CN)C(O)[C@@H]2O)c(=O)nc1N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
MTOR P42345 2/20 0.50
ALDH1A1 P00352 2/20 0.50
THRB P10828 1/20 0.50
MDM2 Q00987 1/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
GMNN O75496 1/20 0.50
TP53 P04637 1/20 0.50
NFKB1 P19838 1/20 0.50
DNMT1 P26358 1/20 0.50
THPO P40225 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
BLM P54132 1/20 0.50
HBB P68871 1/20 0.50
PMP22 Q01453 1/20 0.50
ADK P55263 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21275623 1.00 LMNA (0.50) LMNAMTORALDH1A1THRBMDM2
SCHEMBL14441083 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2
SCHEMBL5953287 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2
SCHEMBL18512948 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2
SCHEMBL6297856 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2
SCHEMBL5953706 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2
SCHEMBL14929291 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2
SCHEMBL5697581 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2
SCHEMBL5888462 0.91 LMNA (0.49) LMNAMTORALDH1A1THRBMDM2
SCHEMBL41572 0.91 LMNA (0.62) LMNAMTORALDH1A1THRBMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2016-08-18 US disclosed
WO-2015051169-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF NSUN3, POLRMT, TRDMT1 LMNA 1343/4885MTOR 4456/4885ALDH1A1 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.